



# MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

MCL/SE/2025-2026

Date: 05.08.2025

Online filing at: [www.listing.bseindia.com](http://www.listing.bseindia.com)

To,  
**The General Manager**  
DCS-CRD  
**BSE Limited**  
Phiroze Jeejeebhoy Towers, 'A' wing  
Dalal Street Fort, Mumbai – 400001 (M.H.)

**SUBJECT: OUTCOME OF BOARD MEETING HELD ON TUESDAY, 05<sup>TH</sup> AUGUST, 2025  
PURSUANT TO REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE  
REQUIREMENTS) REGULATIONS, 2015.**

**REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010)**

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board of Directors at their meeting held on today i.e. Tuesday 05<sup>th</sup> August, 2025 has inter alia considered and approved the following :-

- (1) Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30<sup>th</sup> June, 2025 along with Limited Review Report thereon. (Copy of financial results enclosed herewith).
- (2) Approval of Board's Report on the operations of the Company along with required annexure and Corporate Governance Report and Management Discussion and Analysis Report for the year ended 31<sup>st</sup> March, 2025.
- (3) Convening of 42<sup>nd</sup> Annual General Meeting (AGM) on Thursday, 18<sup>th</sup> September, 2025 at 12.30 P.M. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
- (4) Based on recommendation of the Audit Committee, approval of appointment of Joshi Sahay and Company, Practicing Company Secretaries as Secretarial Auditor of the Company for period of five consecutive years commencing from FY 2025-2026 till FY 2029-2030 and fix their remuneration, subject to approval of the shareholders of the Company at the ensuing 42<sup>nd</sup> Annual General Meeting.
- (5) Based on recommendation of the Nomination and Remuneration Committee, approval of re-appointment of Mr. Dharmendra Solanki (DIN: 09055239) as a Non Executive Independent Director of the Company for a second term of five years w.e.f. 5<sup>th</sup> February, 2026 to 4<sup>th</sup> February, 2031 subject to approval of the shareholders of the Company at the ensuing 42<sup>nd</sup> Annual General Meeting.

---

**REGISTERED OFFICE**

201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA INDORE – 452001

PH:- 0731-4028148, FAX:- 0731-4041435

E mail:- [investors@medicaps.com](mailto:investors@medicaps.com), Web site:- [www.medicaps.com](http://www.medicaps.com)

---



# MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

---

Further, Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 with reference to appointment of Secretarial Auditor and re-appointment of Mr. Dharmendra Solanki Non Executive Independent Director of the Company are being submitted separately in pdf and xbrl form.

(6) Other routine businesses with the permission of Chair.

Further, a copy of aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be submitted in XBRL (Integrated Filing Financial) mode within prescribed time limit.

The aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be uploaded on the Company's website [www.medicaps.com](http://www.medicaps.com) and on the website of the Stock Exchange at [www.bseindia.com](http://www.bseindia.com). Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers within prescribed time limit.

The Meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 03.40 P.M.

The above information will also be available on the website of the Company at [www.medicaps.com](http://www.medicaps.com).

This is for your information and record.

Thanking You,

Yours Faithfully,

**FOR MEDI-CAPS LIMITED**

**ALOK K GARG**  
**MANAGING DIRECTOR**  
**DIN: 00274321**

*Encl.: Un-audited Standalone and Consolidated Financial Results along with limited review report for quarter ended on 30<sup>th</sup> June, 2025.*

---

**REGISTERED OFFICE**

201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA INDORE – 452001

PH:- 0731-4028148, FAX:- 0731-4041435

E mail:- [investors@medicaps.com](mailto:investors@medicaps.com), Web site:- [www.medicaps.com](http://www.medicaps.com)


---

**LIMITED REVIEW REPORT****Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Medi-Caps Limited (the Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To,  
THE BOARD OF DIRECTORS OF  
**MEDI-CAPS LIMITED**

**SCOPE OF THE REVIEW**

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter ended 30<sup>th</sup> June 2025 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), including relevant circulars issued by the SEBI from time to time.
2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the SEBI Listing Regulations.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



## CONCLUSION

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Date:** 05.08.2025

**Place:** Indore

**UDIN:** 25429040BMGSUS7901



**For, Rawka & Associates**  
(Chartered Accountants)

FRN 021606C

*Venus Rawka*  
**Venus Rawka**  
(Partner)

M. No. 429040

# MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435  
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

## UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE 1ST QUARTER ENDED 30.06.2025

(Amount in Laes except EPS)

| S.N.         | Particulars  | Quarter Ended   |                | Year Ended      |                |
|--------------|--|-----------------|----------------|-----------------|----------------|
|              |  | June 30th, 2025 | Mar 31st, 2025 | June 30th, 2024 | Mar 31st, 2025 |
|              |  | (Unaudited)     | (Audited)      | (Unaudited)     | (Audited)      |
| <b>I</b>     | <b>Revenue from Operation</b>  |                 |                |                 |                |
|              | (a) Net sales  | 0.00            | 88.32          | 27.75           | 237.36         |
|              | (b) Other operating income   | 0.00            | 0.76           | 1.27            | 4.30           |
|              | <b>Revenue from Operation</b>  | <b>0.00</b>     | <b>89.08</b>   | <b>29.02</b>    | <b>241.66</b>  |
| <b>II</b>    | <b>Other Income</b>  | <b>31.33</b>    | <b>26.91</b>   | <b>10.72</b>    | <b>56.25</b>   |
| <b>III</b>   | <b>Total income (I+II)</b>   | <b>31.33</b>    | <b>115.99</b>  | <b>39.74</b>    | <b>297.91</b>  |
| <b>IV</b>    | <b>Expenses</b>  |                 |                |                 |                |
|              | a) Cost of material consumed   | 0.00            | 0.00           | 0.00            | 0.00           |
|              | b) Purchase of stock in trade  | 0.00            | 0.00           | 0.00            | 0.00           |
|              | c) Changes in inventories of finished goods, work-in-progress and stock-in-trade   | 0.00            | 0.17           | 0.06            | 0.45           |
|              | d) Employee benefits expense   | 45.67           | 44.91          | 45.23           | 181.05         |
|              | e) Finance costs   | 0.00            | 0.00           | 0.00            | 0.00           |
|              | f) Depreciation and amortisation expense   | 4.00            | 4.00           | 4.00            | 16.01          |
|              | g) Power Cost  | 0.58            | 0.27           | 0.07            | 0.49           |
|              | h) Freight Exp.  | 0.00            | 0.00           | 0.00            | 0.00           |
|              | i) Other expenses  | 20.83           | 23.04          | 23.55           | 71.41          |
|              | <b>Total Expenses (IV)</b>   | <b>71.08</b>    | <b>72.39</b>   | <b>72.91</b>    | <b>269.41</b>  |
| <b>V</b>     | <b>Profit/(Loss) before exceptional item &amp; tax (III-IV)</b>  | <b>-39.75</b>   | <b>43.60</b>   | <b>-33.17</b>   | <b>28.50</b>   |
| <b>VI</b>    | <b>Exceptional items</b>   | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>VII</b>   | <b>Profit/ (Loss) before tax (V-VI)</b>  | <b>-39.75</b>   | <b>43.60</b>   | <b>-33.17</b>   | <b>28.50</b>   |
| <b>VIII</b>  | <b>Tax expense</b>   |                 |                |                 |                |
|              | 1) Current Tax   | 0.00            | 0.00           | 0.00            | 0.00           |
|              | 2) Earlier year (excess)/Short provision for tax written back  | 0.00            | -25.56         | 0.00            | -25.56         |
|              | 3) Deferred Tax  | 0.00            | -1.45          | 0.00            | -1.45          |
|              | <b>Total Tax Expenses</b>  | <b>0.00</b>     | <b>-27.01</b>  | <b>0.00</b>     | <b>-27.01</b>  |
| <b>IX</b>    | <b>Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement</b>        | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>X</b>     | <b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>  | <b>-39.75</b>   | <b>70.61</b>   | <b>-33.17</b>   | <b>55.51</b>   |
| <b>XI</b>    | <b>Profit/(loss) from discontinued operations</b>  | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>XII</b>   | <b>Tax expense of discontinued operations</b>  | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>XIII</b>  | <b>Profit/(loss) from Discontinued operations (after tax) (XI-XII)</b>   | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>XIV</b>   | <b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>                                   | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>XV</b>    | <b>Profit/(loss) for the period (X+XIII)</b>   | <b>-39.75</b>   | <b>70.61</b>   | <b>-33.17</b>   | <b>55.51</b>   |
| <b>XVI</b>   | <b>Other comprehensive income</b>  |                 |                |                 |                |
|              | (a) (i) items that will not be reclassified to statement of profit & loss  | 54.25           | -25.36         | 46.46           | 29.95          |
|              | (ii) Income tax on items that will not be reclassified to statement of P& L  | 0.00            | 0.00           | 0.00            | 0.00           |
|              | (b) (i) items that will be reclassified to statement of profit & loss  | 0.00            | 0.00           | 0.00            | 0.00           |
|              | (ii) Income tax on items that will be reclassified to statement of P& L  | 0.00            | 0.00           | 0.00            | 0.00           |
|              | <b>Other comprehensive income :</b>  | <b>54.25</b>    | <b>-25.36</b>  | <b>46.46</b>    | <b>29.95</b>   |
| <b>XVII</b>  | <b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b> | <b>14.50</b>    | <b>45.25</b>   | <b>13.29</b>    | <b>85.46</b>   |
| <b>XVIII</b> | <b>Profit or Loss Attributable to</b>  |                 |                |                 |                |
|              | Profit or Loss Attributable to owners of Parents   | 0.00            | 0.00           | 0.00            | 0.00           |
|              | Profit or Loss Attributable to non-Controlling Interest  | 0.00            | 0.00           | 0.00            | 0.00           |
| <b>XIX</b>   | <b>Total Comprehensive Income for the period Attributable to</b>   |                 |                |                 |                |
|              | Total Comprehensive Income for the period Attributable to owners of Parents  | 0.00            | 0.00           | 0.00            | 0.00           |
|              | Total Comprehensive Income for the period Attributable to non-Controlling Interest   | 0.00            | 0.00           | 0.00            | 0.00           |

|       |   |         |         |         |         |
|-------|---|---------|---------|---------|---------|
| XX    | Paid-up equity share capital of the company                           | 1247.00 | 1247.00 | 1247.00 | 1247.00 |
| XXI   | Reserve Excluding Revaluation Reserve                                 | 0.00    | 0.00    | 0.00    | 5487.39 |
| XXII  | Earnings per equity share (for continuing operation)                  |         |         |         |         |
|       | a) Basic (Rs.)  | -0.32   | 0.57    | -0.27   | 0.45    |
|       | b) Diluted (Rs.)  | -0.32   | 0.57    | -0.27   | 0.45    |
| XXIII | Earnings per equity share (for discontinued operation)                |         |         |         |         |
|       | a) Basic (Rs.)  | 0.00    | 0.00    | 0.00    | 0.00    |
|       | b) Diluted (Rs.)  | 0.00    | 0.00    | 0.00    | 0.00    |
| XXIV  | Earnings per equity share (for discontinued and continuing operation) |         |         |         |         |
|       | a) Basic (Rs.)  | -0.32   | 0.57    | -0.27   | 0.45    |
|       | b) Diluted (Rs.)  | -0.32   | 0.57    | -0.27   | 0.45    |

DATE: 05.08.2025  
PLACE: INDORE

For and on behalf of board of directors of  
MEDI-CAPS LIMITED

  
ALOK K GARG  
MANAGING DIRECTOR  
DIN: 00274321




**LIMITED REVIEW REPORT****Independent Auditor's Review Report On Consolidated Unaudited Quarterly Financial Results of Medi-Caps Limited (the Parent Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To,  
THE BOARD OF DIRECTORS OF  
**MEDI-CAPS LIMITED**

**SCOPE OF THE REVIEW**

1. We have reviewed the accompanying Statement of the Consolidated Unaudited Financial Results ("the Statement") of Medi-Caps Limited ("the Parent Company") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter ended June 30, 2025, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the SEBI Listing Regulations"), including relevant circular issued by the SEBI time to time.
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would



become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly-owned subsidiary **Medgel Private Limited**.

#### CONCLUSION

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information and explanations given to us by the Parent Company's Management, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of SEBI- (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the financial results of Medgel Private Limited (wholly owned subsidiary) which also has been reviewed by us and certified by the management, whose interim financial results reflect a total income of Rs.268.76 Lakhs, total net loss after tax of Rs. (309.44) Lakhs and total comprehensive income of Rs. 98.18 Lakhs for the quarter ended June 30, 2025 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information/ financial results are not material to the group.

Our Conclusion on the statement is not modified in respect of the above matter.

**Date:** 05.08.2025

**Place:** Indore

**UDIN:** 25429040BMGSUU6666

**For, Rawka & Associates**

Chartered Accountants

FRN 021606C



A handwritten signature in black ink, appearing to be "Venus Rawka".

**Venus Rawka**

(Partner)

M. No. 429040



# MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435  
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

## UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE 1ST QUARTER ENDED 30.06.2025

(Amount in Laes except EPS)

| S.N.         | Particulars  | Quarter Ended   |                | Year Ended      |                |
|--------------|--|-----------------|----------------|-----------------|----------------|
|              |  | June 30th, 2025 | Mar 31st, 2025 | June 30th, 2024 | Mar 31st, 2025 |
|              |  | (Unaudited)     | (Audited)      | (Unaudited)     | (Audited)      |
| <b>I</b>     | <b>Revenue from Operation</b>  |                 |                |                 |                |
|              | (a) Net sales  | 267.65          | 693.51         | 614.56          | 2537.44        |
|              | (b) Other operating income   | 1.11            | 2.84           | 4.88            | 10.27          |
|              | <b>Revenue from Operation</b>  | <b>268.76</b>   | <b>696.35</b>  | <b>619.44</b>   | <b>2547.71</b> |
| <b>II</b>    | <b>Other Income</b>  | <b>33.49</b>    | <b>213.84</b>  | <b>14.59</b>    | <b>272.95</b>  |
| <b>III</b>   | <b>Total income (I+II)</b>   | <b>302.25</b>   | <b>910.19</b>  | <b>634.03</b>   | <b>2820.66</b> |
| <b>IV</b>    | <b>Expenses</b>  |                 |                |                 |                |
|              | a) Cost of material consumed   | 169.19          | 272.25         | 390.62          | 1016.99        |
|              | b) Purchase of stock in trade  | 0.00            | 0.00           | 0.00            | 0.00           |
|              | c) Changes in inventories of finished goods, work-in-progress and stock-in-trade   | -10.35          | 5.36           | -184.45         | 48.17          |
|              | d) Employee benefits expense   | 186.06          | 220.18         | 171.77          | 758.36         |
|              | e) Finance costs   | 1.30            | 2.48           | 0.00            | 2.48           |
|              | f) Depreciation and amortisation expense   | 43.68           | 44.12          | 42.57           | 171.82         |
|              | g) Power Cost  | 53.47           | 41.10          | 43.23           | 167.72         |
|              | h) Freight Exp.  | 39.70           | 20.11          | 38.64           | 137.14         |
|              | i) Other expenses  | 168.39          | 159.76         | 187.30          | 602.09         |
|              | <b>Total Expenses (IV)</b>   | <b>651.44</b>   | <b>765.36</b>  | <b>689.68</b>   | <b>2904.77</b> |
| <b>V</b>     | <b>Profit/(Loss) before exceptional item &amp; tax (III-IV)</b>  | <b>-349.19</b>  | <b>144.83</b>  | <b>-55.65</b>   | <b>-84.11</b>  |
| <b>VI</b>    | <b>Exceptional items</b>   | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>VII</b>   | <b>Profit/ (Loss) before tax (V-VI)</b>  | <b>-349.19</b>  | <b>144.83</b>  | <b>-55.65</b>   | <b>-84.11</b>  |
| <b>VIII</b>  | <b>Tax expense</b>   |                 |                |                 |                |
|              | 1) Current Tax   | 0.00            | 0.00           | 0.00            | 0.00           |
|              | 2) Earlier year (excess)/Short provision for tax written back  | 0.00            | -25.56         | 0.00            | -25.56         |
|              | 3) Deferred Tax  | 0.00            | -1.45          | 0.00            | -1.45          |
|              | <b>Total Tax Expenses</b>  | <b>0.00</b>     | <b>-27.01</b>  | <b>0.00</b>     | <b>-27.01</b>  |
| <b>IX</b>    | <b>Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement</b>        | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>X</b>     | <b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>  | <b>-349.19</b>  | <b>171.84</b>  | <b>-55.65</b>   | <b>-57.10</b>  |
| <b>XI</b>    | <b>Profit/(loss) from discontinued operations</b>  | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>XII</b>   | <b>Tax expense of discontinued operations</b>  | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>XIII</b>  | <b>Profit/(loss) from Discontinued operations (after tax) (XI-XII)</b>   | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>XIV</b>   | <b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>                                   | <b>0.00</b>     | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    |
| <b>XV</b>    | <b>Profit/(loss) for the period (X+XIII)</b>   | <b>-349.19</b>  | <b>171.84</b>  | <b>-55.65</b>   | <b>-57.10</b>  |
| <b>XVI</b>   | <b>Other comprehensive income</b>  |                 |                |                 |                |
|              | (a) (i) items that will not be reclassified to statement of profit & loss  | 152.44          | -159.59        | 159.61          | 86.43          |
|              | (ii) Income tax on items that will not be reclassified to statement of P& L  | 0.00            | 0.00           | 0.00            | 0.00           |
|              | (b) (i) items that will be reclassified to statement of profit & loss  | 0.00            | 0.00           | 0.00            | 0.00           |
|              | (ii) Income tax on items that will be reclassified to statement of P& L  | 0.00            | 0.00           | 0.00            | 0.00           |
|              | <b>Other comprehensive income :</b>  | <b>152.44</b>   | <b>-159.59</b> | <b>159.61</b>   | <b>86.43</b>   |
| <b>XVII</b>  | <b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b> | <b>-196.75</b>  | <b>12.25</b>   | <b>103.96</b>   | <b>29.33</b>   |
| <b>XVIII</b> | <b>Profit or Loss Attributable to</b>  |                 |                |                 |                |
|              | Profit or Loss Attributable to owners of Parents   | -349.19         | 171.84         | -55.65          | -57.10         |
|              | Profit or Loss Attributable to non-Controlling Interest  | 0.00            | 0.00           | 0.00            | 0.00           |
| <b>XIX</b>   | <b>Total Comprehensive Income for the period Attributable to</b>   |                 |                |                 |                |
|              | Total Comprehensive Income for the period Attributable to owners of Parents  | -196.75         | 12.25          | 103.96          | 29.33          |
|              | Total Comprehensive Income for the period Attributable to non-Controlling Interest   | 0.00            | 0.00           | 0.00            | 0.00           |

|       |   |         |         |         |          |
|-------|---|---------|---------|---------|----------|
| XX    | Paid-up equity share capital of the company                           | 1247.00 | 1247.00 | 1247.00 | 1247.00  |
| XXI   | Reserve Excluding Revaluation Reserve                                 | 0.00    | 0.00    | 0.00    | 10880.66 |
| XXII  | Earnings per equity share (for continuing operation)                  |         |         |         |          |
|       | a) Basic (Rs.)  | -2.80   | 1.38    | -0.45   | -0.46    |
|       | b) Diluted (Rs.)  | -2.80   | 1.38    | -0.45   | -0.46    |
| XXIII | Earnings per equity share (for discontinued operation)                |         |         |         |          |
|       | a) Basic (Rs.)  | 0.00    | 0.00    | 0.00    | 0.00     |
|       | b) Diluted (Rs.)  | 0.00    | 0.00    | 0.00    | 0.00     |
| XXIV  | Earnings per equity share (for discontinued and continuing operation) |         |         |         |          |
|       | a) Basic (Rs.)  | -2.80   | 1.38    | -0.45   | -0.46    |
|       | b) Diluted (Rs.)  | -2.80   | 1.38    | -0.45   | -0.46    |

DATE: 05.08.2025  
PLACE: INDORE

For and on behalf of board of directors of  
MEDI-CAPS LIMITED

  
ALOK K GARG  
MANAGING DIRECTOR  
DIN: 00274321

# MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435  
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

## UNAUDITED CONSOLIDATED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE 1ST QUARTER ENDED 30.06.2025

| S.No. | Segment Revenue   | Quarter Ended   |                 |                 | Year Ended      |
|-------|---|-----------------|-----------------|-----------------|-----------------|
|       |   | June 30th, 2025 | Mar 31st, 2025  | June 30th, 2024 | Mar 31st, 2025  |
|       |   | Unaudited       | Audited         | Unaudited       | Audited         |
| 1     | <b>Segment Revenue</b>  |                 |                 |                 |                 |
|       | Pharma Division   | 268.76          | 607.27          | 590.42          | 2306.05         |
|       | Real Estate Division  | 0.00            | 89.08           | 29.02           | 241.66          |
|       | Other   | 0.00            | 0.00            | 0.00            | 0.00            |
|       | <b>Net Sale/Income From Operations</b>                                | <b>268.76</b>   | <b>696.35</b>   | <b>619.44</b>   | <b>2547.71</b>  |
| 2     | <b>Segment Results (Profit) (+)/ Loss (-) before tax and Interest</b> |                 |                 |                 |                 |
|       | Pharma Division   | -308.14         | 103.71          | -22.48          | -110.13         |
|       | Real Estate Division  | -39.75          | 43.60           | -33.17          | 28.50           |
|       | Other   | 0.00            | 0.00            | 0.00            | 0.00            |
|       | <b>Total</b>  | <b>-347.89</b>  | <b>147.31</b>   | <b>-55.65</b>   | <b>-81.63</b>   |
|       | Interest Income   | 0.00            | 0.00            | 0.00            | 0.00            |
|       | Interest Expenses   | 1.30            | 2.48            | 0.00            | 2.48            |
|       | Other Unallocable Expenditure net off                                 | 0.00            | 0.00            | 0.00            | 0.00            |
|       | Unallocable Income  | 0.00            | 0.00            | 0.00            | 0.00            |
|       | <b>Profit Before Tax</b>  | <b>-349.19</b>  | <b>144.83</b>   | <b>-55.65</b>   | <b>-84.11</b>   |
| 3     | <b>Capital Employed</b>   |                 |                 |                 |                 |
|       | <b>Segment Assets (A)</b>   |                 |                 |                 |                 |
|       | Pharma Division   | 5491.74         | 5739.66         | 6058.94         | 5739.66         |
|       | Real Estate Division  | 6810.76         | 6802.66         | 6728.74         | 6802.66         |
|       | Other   | 0.00            | 0.00            | 0.00            | 0.00            |
|       | <b>Total (A)</b>  | <b>12302.50</b> | <b>12542.32</b> | <b>12787.68</b> | <b>12542.32</b> |
|       | <b>Segment Liabilities (B)</b>  |                 |                 |                 |                 |
|       | Pharma Division   | 309.72          | 346.40          | 518.86          | 346.40          |
|       | Real Estate Division  | 61.86           | 68.27           | 66.52           | 68.27           |
|       | Other   | 0.00            | 0.00            | 0.00            | 0.00            |
|       | <b>Total (B)</b>  | <b>371.58</b>   | <b>414.67</b>   | <b>585.38</b>   | <b>414.67</b>   |
| 4     | <b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>    |                 |                 |                 |                 |
|       | Pharma Division   | 5182.02         | 5393.27         | 5540.08         | 5393.27         |
|       | Real Estate Division  | 6748.90         | 6734.39         | 6662.23         | 6734.39         |
|       | Other   | 0.00            | 0.00            | 0.00            | 0.00            |
|       | <b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>    | <b>11930.92</b> | <b>12127.66</b> | <b>12202.30</b> | <b>12127.66</b> |

DATE: 05.08.2025  
PLACE: INDORE

For and on behalf of board of directors of  
MEDI-CAPS LIMITED

  
**ALOK K GARG**  
MANAGING DIRECTOR  
DIN: 00274321

**NOTES:**

1. The above standalone and consolidated unaudited financial results for the Quarter ended June 30, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on August 05, 2025. The above results have been reviewed by Statutory Auditors of the Company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised the necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. This above standalone and consolidated unaudited financial results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated results included the results of the wholly owned subsidiary company i.e. Medgel Private Limited.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists of the Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and the same is enclosed with this result.
5. The Company has not generated any revenue from operation during this quarter.
6. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.
7. The aforesaid unaudited financial Results will be uploaded on the Company's website [www.medicaps.com](http://www.medicaps.com) and will also be available on the websites of the Stock exchange i.e. [www.bseindia.com](http://www.bseindia.com) for the benefit of shareholders and investors. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available, will be published in English and Hindi Newspapers with in prescribed time limit.
8. The figures of the quarter ended March 31, 2025 are the balancing figure between the audited figures in respect of the full financial year and the years to date figures up to the up to the first quarter which were subject to limited review.

**DATE: 05.08.2025**

**PLACE: INDORE**

**For and on behalf of the Board of Directors of**

**MEDI-CAPS LIMITED**

  
**ALOK K GARG**  
**MANAGING DIRECTOR**  
**DIN: 00274321**